Latest news with #BioVie
Miami Herald
12-07-2025
- Business
- Miami Herald
New to The Street Episode #678 to Air on Bloomberg TV Featuring Game-Changing Innovators in AI, Biotech, Blockchain, and Sustainability
Broadcast Premieres Saturday, July 12 at 6:30 PM EST on Bloomberg Television NEW YORK CITY, NY / ACCESS Newswire / July 12, 2025 / New to The Street, the leading multi-platform financial news series, announces its upcoming Bloomberg Television broadcast, airing Saturday, July 12 at 6:30 PM EST. Episode #678 showcases five transformative companies leading advancements across artificial intelligence, healthcare, sustainability, and blockchain. This dynamic lineup brings powerful insights from visionary leaders shaping the future of their respective industries. Featured Segments in Episode #678: Hapbee Technologies (OTCQB:HAPBF)NBA All-Star Jaylen Brown shares how Hapbee's groundbreaking wearable neurotech helps optimize sleep, recovery, and cognitive performance-without pharmaceuticals. The device uses proprietary low-frequency signals to emulate the effects of popular compounds, empowering users to choose how they feel, naturally and safely. Arrive AI (NASDAQ:ARAI)Live from Nasdaq MarketSite in Times Square, host Ana Berry interviews CEO Dan O'Toole and Chief Strategy Officer Neerav Shah as they unveil Arrive's secure smart mailbox technology. Phase 1 launches in healthcare and logistics; Phase 2 expands to every U.S. ZIP code. Arrive beat Amazon to the patent by four days, reinforcing its first-mover advantage in the $150B+ last-mile delivery sector. FLOKI (CRYPTO:FLOKI)Pedro Vidal, FLOKI's Community Relations Officer, discusses the explosive success of Valhalla, its play-to-earn metaverse game. As FLOKI expands across DeFi, NFTs, and blockchain gaming, its highly engaged global community cements it as one of crypto's most disruptive and culturally relevant brands. Learn more at BioVie Inc. (NASDAQ:BIVI)CEO Cuong Do and Chief Medical Officer Joseph Palumbo join Jane King to share meaningful updates on BioVie's advancement in clinical trials targeting Alzheimer's, Parkinson's, and Long COVID. BioVie is the only company to receive a federal grant to study Long COVID, and is currently enrolling patients in a 200‑person clinical trial. They also introduce Social Impact Partners, a nonprofit initiative to foster collaboration across the private, public, and government sectors in supporting Alzheimer's patients. The segment touches on promising new research around BioVie's investigational drug Bezisterim, which may reduce cellular "rust buildup"-a key contributor to aging. Initial findings suggest it could play a role in slowing the aging process. The Sustainable Green Team (OTC:SGTM)CEO Tony Raynor outlines how SGTM transforms organic landfill waste into premium garden and soil products. What began as a mulch and tree removal business is now a regenerative brand with Amazon-ready offerings and national retail ambitions. SGTM is on a mission to restore soil health across America. Learn more at This episode is presented as sponsored programming on Bloomberg Television, reaching more than 124 million households nationwide. Further distribution includes: New to The Street's YouTube channel with 3 million+ subscribersEarned media coverage across major networksIconic outdoor billboards in Times Square and major U.S. metros Sponsors for Episode #678 include MUSQ, and Arrive AI TV Commercials. Media Contact:Monica BrennanNew to The Street - Media RelationsMonica@ Watch & Learn More: SOURCE: New to The Street
USA Today
12-07-2025
- Business
- USA Today
New to The Street Episode #678 to Air on Bloomberg TV Featuring Game-Changing Innovators in AI, Biotech, Blockchain, and Sustainability
Broadcast Premieres Saturday, July 12 at 6:30 PM EST on Bloomberg Television New to The Street, the leading multi-platform financial news series, announces its upcoming Bloomberg Television broadcast, airing Saturday, July 12 at 6:30 PM EST. Episode #678 showcases five transformative companies leading advancements across artificial intelligence, healthcare, sustainability, and blockchain. This dynamic lineup brings powerful insights from visionary leaders shaping the future of their respective industries. Featured Segments in Episode #678: Hapbee Technologies (OTCQB:HAPBF) NBA All-Star Jaylen Brown shares how Hapbee's groundbreaking wearable neurotech helps optimize sleep, recovery, and cognitive performance-without pharmaceuticals. The device uses proprietary low-frequency signals to emulate the effects of popular compounds, empowering users to choose how they feel, naturally and safely. Arrive AI (NASDAQ:ARAI) Live from Nasdaq MarketSite in Times Square, host Ana Berry interviews CEO Dan O'Toole and Chief Strategy Officer Neerav Shah as they unveil Arrive's secure smart mailbox technology. Phase 1 launches in healthcare and logistics; Phase 2 expands to every U.S. ZIP code. Arrive beat Amazon to the patent by four days, reinforcing its first-mover advantage in the $150B+ last-mile delivery sector. FLOKI (CRYPTO:FLOKI) Pedro Vidal, FLOKI's Community Relations Officer, discusses the explosive success of Valhalla, its play-to-earn metaverse game. As FLOKI expands across DeFi, NFTs, and blockchain gaming, its highly engaged global community cements it as one of crypto's most disruptive and culturally relevant brands. Learn more at BioVie Inc. (NASDAQ:BIVI) CEO Cuong Do and Chief Medical Officer Joseph Palumbo join Jane King to share meaningful updates on BioVie's advancement in clinical trials targeting Alzheimer's, Parkinson's, and Long COVID. BioVie is the only company to receive a federal grant to study Long COVID, and is currently enrolling patients in a 200‑person clinical trial. They also introduce Social Impact Partners, a nonprofit initiative to foster collaboration across the private, public, and government sectors in supporting Alzheimer's patients. The segment touches on promising new research around BioVie's investigational drug Bezisterim, which may reduce cellular 'rust buildup'-a key contributor to aging. Initial findings suggest it could play a role in slowing the aging process. The Sustainable Green Team (OTC:SGTM) CEO Tony Raynor outlines how SGTM transforms organic landfill waste into premium garden and soil products. What began as a mulch and tree removal business is now a regenerative brand with Amazon-ready offerings and national retail ambitions. SGTM is on a mission to restore soil health across America. Learn more at This episode is presented as sponsored programming on Bloomberg Television, reaching more than 124 million households nationwide. Further distribution includes: New to The Street's YouTube channel with 3 million+ subscribers Earned media coverage across major networks Iconic outdoor billboards in Times Square and major U.S. metros Sponsors for Episode #678 include MUSQ, and Arrive AI TV Commercials. 'We're proud to deliver this high‑impact episode featuring leaders from five of the most innovative sectors,' said Vince Caruso, Co‑Founder and Executive Producer of New to The Street. 'This show exemplifies our mission to present breakthrough companies and ideas with credibility, scale, and reach.' Media Contact: Monica Brennan New to The Street – Media Relations Monica@ Watch & Learn More: SOURCE: New to The Street View the original press release on ACCESS Newswire
Business Insider
06-07-2025
- Business
- Business Insider
Upcoming Stock Splits This Week (July 7 to July 11)
These are the upcoming stock splits for the week of July 7 to July 11, based on TipRanks' Stock Splits Calendar. For those new to the concept, a stock split is a corporate strategy that increases the number of shares in circulation by granting existing shareholders additional shares. While this move doesn't change the company's overall market value, it does lower the share price, making the stock more affordable, and often more appealing, to everyday investors. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. But it's not always about making shares cheaper. Some companies go in the opposite direction with a reverse stock split, combining shares to boost the price per share while reducing the total number. This maneuver, which also leaves the company's market value untouched, is often used to meet exchange requirements and avoid the risk of delisting. Whether the goal is to attract a broader base of investors or simply to stay in the game, these corporate moves can send important signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. Fly-E Group (FLYE) – Fly-E designs and sells smart electric motorcycles, bikes, and scooters for urban commuters and adventure-seekers alike. On July 2, the company announced a 1-for-5 reverse stock split to boost its share price and remain in compliance with Nasdaq listing standards. The split becomes effective July 7, when shares begin trading on a split-adjusted basis. BioVie (BIVI) – BioVie is a biopharmaceutical innovator working to develop therapies for NASH and other serious fibrotic diseases. On June 26, the company approved a 1-for-10 reverse stock split aimed at raising the share price above Nasdaq's minimum threshold. The split will be reflected in trading starting July 7. Revelation Biosciences (REVB) – With its sights set on breakthrough treatments for chronic kidney disease, Revelation Biosciences is taking proactive steps to stay ahead. The company announced a 1-for-3 reverse stock split to meet Nasdaq's listing standards, following approval at its Special Meeting of Stockholders held on June 23. The split will take effect on July 7. Cyclacel Pharmaceuticals (CYCC) – Cyclacel Pharmaceuticals is a clinical-stage biotech working to create small-molecule cancer drugs that may redefine oncology treatment. On July 2, the company announced a 1-for-15 reverse stock split to keep its shares above Nasdaq's minimum price requirement. The split will be in effect starting July 7. Nuwellis (NUWE) – Nuwellis, a trailblazer in medical-tech fluid management tools for heart and kidney patients, has finalized its 1-for-42 reverse stock split. The split became effective after the close of business on July 3, and trading on a split-adjusted basis will begin at the open on Monday, July 7. La Rosa Holdings (LRHC) – La Rosa is a real estate brokerage and PropTech company serving residential markets across the United States. On July 2, the company announced an 80-for-1 reverse stock split to comply with Nasdaq's minimum bid price. The split will be effective July 7. Banzai International (BNZI) – Banzai delivers essential marketing and sales technology solutions to businesses globally. On July 3, the company announced a 1‑for‑10 reverse stock split, designed to lift its per-share price and comply with Nasdaq's $1 minimum bid requirement following a steep share-price decline. This split will be effective at market open on July 8. Boqii Holding Limited (BQ) – Boqii is China's leading e-commerce platform for pet products. On July 1, the company announced a 1‑for‑160 reverse stock split, consolidating every 160 ordinary shares into one and terminating its ADS facility to simplify its NYSE American listing. The split becomes effective on July 11.
Yahoo
24-06-2025
- Health
- Yahoo
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) ('BioVie' or the 'Company') a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27 to June 30, 2025. Details for the poster session are as follows: Title: SUNRISE-PD: An Ongoing, Hybrid, Decentralized Phase 2 Study of Bezisterim (NE3107) in Early Parkinson's DiseasePoster session: 11:30am to 12:30pm, Friday June 27Authors: Mark Stacy; Clarence Ahlem; Christopher L. Reading; Jeffrey Zhang; Joseph M. PalumboPoster position: P 49Poster displayed from 7:00am Friday June 27 through 2:00pm Sunday June 29 SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety follow up. As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committee. If the trial's results are positive, participants may be eligible to enter a longer-term, open-label safety study. About Parkinson's Disease Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Core symptoms include tremors, muscle rigidity, bradykinesia (slowness of movement), postural instability, and difficulties with speech.1-2 Non-motor symptoms, such as cognitive impairment, mood disorders, and autonomic dysfunction, also significantly impact patients' quality of life.3 In the early stages, symptoms are often mild and may include subtle tremors, slight movement difficulties, and changes in handwriting or facial expressions. As the disease progresses, motor symptoms become more pronounced, leading to difficulties with balance, speech, and daily activities, often requiring full-time care in later stages.4 Since the 1960s, when dopamine's critical role in Parkinson's disease was first identified, levodopa has remained the cornerstone of treatment, providing significant symptom relief by replenishing dopamine levels in the brain.5-6 However, long-term use is associated with complications such as motor fluctuations—where symptom control becomes less stable—and dyskinesia, involuntary movements that can become debilitating.7-9 Emerging research highlights the role of chronic inflammation and insulin resistance in the onset and progression of Parkinson's disease. Neuroinflammation, driven by activated microglia and elevated levels of pro-inflammatory cytokines, contributes to oxidative stress and accelerates neuronal degeneration.10-12 Additionally, insulin resistance, which impairs the brain's ability to regulate glucose metabolism, has been linked to increased neurodegeneration and worsening motor symptoms.13-14 These metabolic dysfunctions create a harmful cycle that exacerbates disease progression, underscoring the potential of anti-inflammatory and insulin-sensitizing therapies as new avenues for treatment. About Bezisterim Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID. In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in 'morning on' symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events. In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ('brain fog') and fatigue. In Alzheimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. References 1 Cleveland Clinic. Parkinson's Disease. Last reviewed: 2022 Apr 15.2 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.3 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.4 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.5 Hornykiewicz O. Angew Chem Int Ed. 2002;41(17):2934-2941.6 Olanow CW, Obeso JA and Stocchi F. Lancet Neurol. 2006;5(8):677-687.7 Ahlskog JE and Muenter MD. Mov Disord. 2001;16(3):448-458.8 Espay AJ, Morgante F, Merola A, et al. Ann Neurol. 2018;84(6):797-811.9 Cilia R and Akpalu A. J Neural Transm. 2020;127(5):889-916.10 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.11 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.12 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.13 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.14 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16): Chuck Padala Managing Director LifeSci Advisors, LLC chuck@ Melyssa WeibleManaging Partner, Elixir Health Public Relations Ph: +1 201-723-5705mweible@
Miami Herald
16-05-2025
- Business
- Miami Herald
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / May 16, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: BIVI: In an exclusive interview, Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share how BioVie is unlocking the science of longevity through novel therapeutics targeting neurodegenerative diseases and advanced liver conditions. Do highlights the Company's lead drug candidate, bezisterim, a first-in-class small molecule designed to combat chronic inflammation and insulin resistance-key drivers in Alzheimer's and Parkinson's disease, as well as Long COVID. He also discusses BIV201, BioVie's Orphan-designated liver therapy being developed to treat - and may become the first approved treatment - for ascites, an end-stage liver disease condition of 50%+ mortality rate in 12 months. With multiple clinical programs advancing across Phase 2 and Phase 3 trials and a clear path toward commercialization, BioVie is positioned at the forefront of transformative healthcare innovation. Pete O'Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company's dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star's 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development while minimizing shareholder dilution. The company's experienced leadership and strategic positioning in one of North America's most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success. BIVI and LBSR are clients of RedChip Companies. Please read our full disclosure at About BioVie Inc. BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit About Liberty Star Liberty Star Uranium & Metals Corp. (LBSR:OTCQB), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently the company controls properties that are located over what management considers some of North America's richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company's premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA. Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
